Efficacy of Oral Tofacitinib in Refractory Chronic Spontaneous Urticaria and Urticarial Vasculitis

Efficacy of Oral Tofacitinib in Refractory Chronic Spontaneous Urticaria and Urticarial Vasculitis Publisher Pubmed

Mansouri P¹ ; Mozafari N^{2, 3} ; Chalangari R⁴ ; Martitschalangari K⁴

Show Affiliations

1. Medical Laser Research Centers, Academic Center of Education, Culture and Research, Tehran University of Medical Sciences, Tehran, Iran
2. Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Department of Dermatology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4. Dermatology Department, Kassir Dermatology, Dallas, TX, United States

Source: Dermatologic Therapy Published:2022

Abstract

The treatment of chronic urticaria (CU) is difficult, currently, antihistamines (AH) are the mainstay of treatment, however, up to 40% of patients do not respond to even high (four-fold) daily doses of AH. Tofacitinib is, a small-molecule that blocks JAK1/3 and inhibits intracellular signaling of multiple key cytokines involved in the inflammatory cascade and its beneficial effects were reported in patients with mast cell activation disease but there is no report in patients with urticaria. Here, we present four cases of refractory CU and one case of urticarial vasculitis (UV) that were managed with tofacitinib. Despite the long-term unresponsiveness of various treatments in our patients, the addition of tofacitinib significantly improved the urticarial activity and ultimately led to tapering and discontinuation of cyclosporine or AH. In conclusion, tofacitinib appears to downregulate inflammatory phenomena associated with mast cells and might be a new therapeutic option for patients with refractory CU or UV. © 2022 Wiley Periodicals LLC.

Style	Citing Format
MLA	Mansouri P, et al.. "Efficacy of Oral Tofacitinib in Refractory Chronic Spontaneous Urticaria and Urticarial Vasculitis." Dermatologic Therapy, vol. 35, no. 12, 2022, pp. -.
APA	Mansouri P, Mozafari N, Chalangari R, Martitschalangari K (2022). Efficacy of Oral Tofacitinib in Refractory Chronic Spontaneous Urticaria and Urticarial Vasculitis. Dermatologic Therapy, 35(12), -.
Chicago	Mansouri P, Mozafari N, Chalangari R, Martitschalangari K. "Efficacy of Oral Tofacitinib in Refractory Chronic Spontaneous Urticaria and Urticarial Vasculitis." Dermatologic Therapy 35, no. 12 (2022): -.
Harvard	Mansouri P et al. (2022) 'Efficacy of Oral Tofacitinib in Refractory Chronic Spontaneous Urticaria and Urticarial Vasculitis', Dermatologic Therapy, 35(12), pp. -.
Vancouver	Mansouri P, Mozafari N, Chalangari R, Martitschalangari K. Efficacy of Oral Tofacitinib in Refractory Chronic Spontaneous Urticaria and Urticarial Vasculitis. Dermatologic Therapy. 2022;35(12):-.
BibTex	@article{ author = {Mansouri P and Mozafari N and Chalangari R and Martitschalangari K}, title = {Efficacy of Oral Tofacitinib in Refractory Chronic Spontaneous Urticaria and Urticarial Vasculitis}, journal = {Dermatologic Therapy}, volume = {35}, number = {12}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Mansouri P AU - Mozafari N AU - Chalangari R AU - Martitschalangari K TI - Efficacy of Oral Tofacitinib in Refractory Chronic Spontaneous Urticaria and Urticarial Vasculitis JO - Dermatologic Therapy VL - 35 IS - 12 SP - EP - PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract